Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Annie G. Cox, Sarah A. Marshall, Kirsten R. Palmer & Euan M. Wallace. (2019) Current and emerging pharmacotherapy for emergency management of preeclampsia. Expert Opinion on Pharmacotherapy 20:6, pages 701-712.
Read now
Read now
Mark Pucci, Nadia Sarween, Ellen Knox, Graham Lipkin & Una Martin. (2015) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in women of childbearing age: risks versus benefits. Expert Review of Clinical Pharmacology 8:2, pages 221-231.
Read now
Read now
Articles from other publishers (21)
Yuan Liu, Ruonan Zhai, Jiahao Tong, Ying Yu, Lin Yang, Yong Gu & Jianying Niu. (2022) Angiotensin 1-7 and its analogue decrease blood pressure but aggravate renal damage in preeclamptic mice. Experimental Animals 71:4, pages 519-528.
Crossref
Crossref
Jessica Saunders, Allison Marie Callejas Salgado, Joseph Y Ting, Cherry Mammen, Jefferson Terry & Jonathan W Bush. (2021) Quantifying Proximal Collecting Tubule Deficiency in Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Fetopathy. Pediatric and Developmental Pathology 24:5, pages 438-444.
Crossref
Crossref
Qiang Wei, Li Zhang, Mei-fan Duan, Yue-mei Wang, Nan Huang & Chun-rong Song. (2021) Use of angiotensin II receptor blocker during pregnancy. Medicine 100:3, pages e24304.
Crossref
Crossref
Y K Onno Teng, Edwin O W Bredewold, Ton J Rabelink, Tom W J Huizinga, H C Jeroen Eikenboom, Maarten Limper, Ruth D E Fritsch-Stork, Kitty W M Bloemenkamp & Marieke Sueters. (2018) An evidence-based approach to pre-pregnancy counselling for patients with systemic lupus erythematosus. Rheumatology 57:10, pages 1707-1720.
Crossref
Crossref
Louise M Webster, Andrew J Webb & Lucy C Chappell. (2018) What is the evidence for using labetalol as a first-line treatment option for hypertension in pregnancy?. Drug and Therapeutics Bulletin 56:9, pages 107-111.
Crossref
Crossref
. 2017. High-Risk Pregnancy. High-Risk Pregnancy.
Philip Webster, Liz Lightstone, Dianne B. McKay & Michelle A. Josephson. (2017) Pregnancy in chronic kidney disease and kidney transplantation. Kidney International 91:5, pages 1047-1056.
Crossref
Crossref
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs
317
319
.
Chisa Shimada, Rina Akaishi, Kazutoshi Cho, Mamoru Morikawa, Yosuke Kaneshi, Takahiro Yamda & Hisanori Minakami. (2015) Outcomes of 83 fetuses exposed to angiotensin receptor blockers during the second or third trimesters: a literature review. Hypertension Research 38:5, pages 308-313.
Crossref
Crossref
Maria Paz Ocaranza, Luis Michea, Mario Chiong, Carlos F. Lagos, Sergio LavanderoJorge E. Jalil. (2014) Recent insights and therapeutic perspectives of angiotensin-(1–9) in the cardiovascular system. Clinical Science 127:9, pages 549-557.
Crossref
Crossref
Maria Paz Ocaranza, Jackeline Moya, Victor Barrientos, Rodrigo Alzamora, Daniel Hevia, Cristobal Morales, Melissa Pinto, Nicolás Escudero, Lorena García, Ulises Novoa, Pedro Ayala, Guillermo Díaz-Araya, Ivan Godoy, Mario Chiong, Sergio Lavandero, Jorge E. Jalil & Luis Michea. (2014) Angiotensin-(1–9) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme/Ang II axis. Journal of Hypertension 32:4, pages 771-783.
Crossref
Crossref
Ian Blumer, Eran Hadar, David R Hadden, Lois Jovanovič, Jorge H Mestman, M Hassan Murad & Yariv Yogev. (2013) Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism 98:11, pages 4227-4249.
Crossref
Crossref
Emmanuel Spaggiari, Laurence Heidet, Gilles Grange, Fabien Guimiot, Sophie Dreux, Anne-Lise Delezoide & Françoise Muller. (2012) Prognosis and outcome of pregnancies exposed to renin-angiotensin system blockers. Prenatal Diagnosis 32:11, pages 1071-1076.
Crossref
Crossref
Daniel Biermann, Andreas Heilmann, Michael Didié, Saskia Schlossarek, Azadeh Wahab, Michael Grimm, Maria Römer, Hermann Reichenspurner, Karim R. Sultan, Anna Steenpass, Süleyman Ergün, Sonia Donzelli, Lucie Carrier, Heimo Ehmke, Wolfram H. Zimmermann, Lutz Hein, Rainer H. Böger & Ralf A. Benndorf. (2012) Impact of AT2 Receptor Deficiency on Postnatal Cardiovascular Development. PLoS ONE 7:10, pages e47916.
Crossref
Crossref
Marina BulloSibylle TschumiBarbara S. BucherMario G. BianchettiGiacomo D. Simonetti. (2012) Pregnancy Outcome Following Exposure to Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Antagonists. Hypertension 60:2, pages 444-450.
Crossref
Crossref
Janine E. Polifka. (2012) Is there an embryopathy associated with first-trimester exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists? A critical review of the evidence. Birth Defects Research Part A: Clinical and Molecular Teratology 94:8, pages 576-598.
Crossref
Crossref
Vellore J Karthikeyan, Robin E Ferner, Sabah Baghdadi, Deirdre A Lane, Gregory YH Lip & D Gareth Beevers. (2011) Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers safe in pregnancy: a report of ninety-one pregnancies. Journal of Hypertension 29:2, pages 396-399.
Crossref
Crossref
Belinda Jim, Shuchita Sharma, Tewabe Kebede & Anjali Acharya. (2010) Hypertension in Pregnancy. Cardiology in Review 18:4, pages 178-189.
Crossref
Crossref
Baha M. Sibai. 2010. A Practical Manual of Diabetes in Pregnancy. A Practical Manual of Diabetes in Pregnancy
153
164
.
Jamie J. Coleman & Tehreem F. Butt. 2010. Side Effects of Drugs Annual 32 - A worldwide yearly survey of new data and trends in adverse drug reactions and interactions. Side Effects of Drugs Annual 32 - A worldwide yearly survey of new data and trends in adverse drug reactions and interactions
375
400
.
Rebecca L Branch & Una Martin. (2007) Adverse effects of angiotensin-converting enzyme inhibitors and Angiotensin-II receptor blockers in pregnancy. Adverse Drug Reaction Bulletin &NA;:246, pages 943-946.
Crossref
Crossref